Daiichi Sankyo raises first-half outlook on strong generic valaciclovir sales
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo has raised its sales and profit guidance for the first half of the current fiscal year on expectations of a better than expected performance from its Ranbaxy generics subsidiary.